Lantern Pharma Inc.
LTRN
$3.59
-$0.03-0.83%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -5.88M | -4.51M | -4.96M | -5.44M | -4.19M |
| Total Depreciation and Amortization | 51.20K | 47.90K | 46.30K | 45.10K | 164.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 538.90K | -210.10K | 24.20K | 196.30K | -242.90K |
| Change in Net Operating Assets | 1.31M | -914.30K | -301.60K | 2.13M | 879.20K |
| Cash from Operations | -3.97M | -5.58M | -5.19M | -3.07M | -3.39M |
| Capital Expenditure | -3.10K | -3.00K | -4.30K | -2.20K | -5.10K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.45M | 683.40K | -197.80K | -554.00K | 261.30K |
| Cash from Investing | 3.45M | 680.30K | -202.10K | -556.20K | 256.20K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 12.00K | 0.00 | 54.70K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -500.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00 | 12.00K | 0.00 | 54.70K | -500.00K |
| Foreign Exchange rate Adjustments | -67.20K | 16.20K | 11.30K | -9.80K | -4.80K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -591.70K | -4.87M | -5.38M | -3.58M | -3.63M |